Macrocytic anaemia in patients treated with sulphasalazine for rheumatoid arthritis.

Affordable Access

Macrocytic anaemia in patients treated with sulphasalazine for rheumatoid arthritis.

Publication Date
Feb 07, 1987
  • Biology
  • Medicine


Tofacitinib for the Treatment of Rheumatoid Arthritis The full report is titled “Tofacitinib in Combination With Nonbiologic Disease- Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis. A Randomized Trial.” It is in the 20 August 2013 issue of Annals of Internal Medicine (volume 159, pages 253-261). The authors are J. Kremer, Z.G. Li, S. Hall, R. Fleischmann, M. Genovese, E. Martin-Mola, J.D. Isaacs, D. Gruben, G. Wallenstein, S. Krishnaswami, S.H. Zwillich, T. Koncz, R. Riese, and J. Bradley. What is the problem and what is known about it so far? Patients with rheumatoid arthritis (RA) have debilitating pain, stiffness, and swelling of joints. The response to various drugs or drug combination of them may be inadequate, or some patients may develop problems with some of these treatments, leaving them with persistent symptoms. Tofacitinib is a drug that alters the activity of immune cells and the process of inflammation involved in RA, so it might be a useful treatment for some patients with RA. Why did the researchers do this particular study? To find out if tofacitinib can improve symptoms and be safely used in patients with RA who still have bad symptoms despite other treatments. Who was studied? 792 patients with ongoing RA despite previous drug treatments, including methotrexate, leflunomide, sulfasalazine, and hydroxychloroquine or a combination of such drugs. How was the study done? Patients continued with their established RA treatments and were randomly assigned to receive either of 2 doses of tofacitinib or placebo. They took tofacitinib or placebo pills each day. The researchers evaluated whether measurements of the disease’s activity changed after 3 and 6 months. They also monitored blood work to see if any problems occurred and recorded any bad side effects over 12 months. What did the researchers find? More patients receiving either dose of tofacitinib had an improvement in the activity of their RA than tho

Report this publication


Seen <100 times